Medicare's GLP-1 coverage program has grown to 700,000 seniors, according to Eli Lilly CEO David Ricks. He said Lilly holds 70% of that market, a figure that highlights the company's dominance in the category as the program expands.
Ricks made the comments as sign-ups continue to climb, suggesting sustained appetite for GLP-1 treatments among Medicare beneficiaries. The report is based on a single source, so there are no independent figures or contrasting views to compare against, but the numbers offer a snapshot of the competitive landscape.
The growth of the program and Lilly's large share point to the commercial stakes in the GLP-1 market, where demand has surged beyond initial expectations. Further enrollment data will show whether Lilly can maintain that position as other manufacturers compete for Medicare patients.